Group items tagged

Pfizer's oral Covid-19 therapy will be evaluated as a potential treatment for patients hospitalised with the illness in a major British trial, scientists said on Monday, as cases rise in some parts of the world. The world's largest randomised study of potential medicines for Covid-19, dubbed the RECOVERY trial, will assess Paxlovid across hospitals in Britain, which has already approved the drug for early-stage treatment. "Paxlovid is a promising oral antiviral drug but we don't know if it can improve survival of patients with severe Covid-19," said Peter Horby, a professor at the University of Oxford and joint chief investigator of the RECOVERY trial. The scientists said they aim to mainly find whether Pfizer's Paxlovid reduces the risk of death among patients admitted to hospitals with Covid-19.

Pharmacy teams are being encouraged to support the ground-breaking Platform Adaptive trial of Novel antivirals for early treatment of Covid-19 In the Community (PANORAMIC) study by raising awareness among patients. The study aims to find out whether new antiviral treatments can help Covid-19 patients avoid hospital admission and support a quicker recovery. The PANORAMIC trial will allow researchers to gather data on the potential benefits of treatments to patients and will help the NHS to develop plans for rolling out the products to further patients in 2022. Anyone over the age of 50 or between 18 to 49 with certain underlying health conditions can participate in the trial after receiving a positive PCR or lateral flow test result for Covid-19. People who wish to participate in the trial can sign up themselves through the study's website and may be contacted by a member of the clinical team in a general practice that has been set up to deliver the PANORAMIC trial.

The Pharmacists' Defence Association (PDA) has raised the issue faced by the pharmacy students on returning to in-person assessments while urging the universities to take an empathetic approach in transition of online to in-person exams. It was highlighted by the association that many student members were apprehensive about the return to in-person assessments. This is due to their continuing worry of Covid-19 transmissions and anxiety caused by changing exam formats and procedures. However, with the ease of Covid restrictions, now pharmacy schools are able to decide how exams are conducted but the PDA believes that they should communicate the process to students in advance. "A return to normal university life is considered to be beneficial to student health and well-being. In-person exams are an important part of preparing for students' future trainee assessment examinations, GPhC accreditation for pharmacy schools, and ensuring the integrity of exam results. As future healthcare professionals, face-to-face interaction is also an integral part of the role," said the PDA.

The UK Health Security Agency (UKHSA) and the Office for National Statistics (ONS) will jointly launch a new study to gather data on COVID-19 this winter. The Winter COVID-19 Infection Study (WCIS) will run from November 2023 to March 2024, involving up to 200,000 participants, UKHSA has said on Monday (October 2). UKHSA previously commissioned the Coronavirus Infection Survey (CIS), conducted by the ONS in collaboration with scientific study leaders from Oxford University, analysing more than 11.5 million swab tests and 3 million blood tests from April 2020 to March 2023. Meanwhile, the Winter CIS study involves conducting up to 32,000 lateral flow tests weekly, providing vital insights into COVID-19 prevalence in the broader community. The sample will be structured to broadly reflect key population characteristics.

It's no secret that as pharmacists we are navigating a new and more demanding healthcare landscape. Our role has changed significantly since the start of the 21st century due to increased expectations from the public, advances in science and technology and changing workforce pressures. The Community Pharmacy Contractual Framework for England has placed a higher focus on clinical service. In addition, the Covid-19 pandemic resulted in significant acceleration in changing how we work day-to-day and the public perception of our role. Community pharmacy owners and staff have been under relentless pressure for the last two years. Dispensing volumes are continually increasing but dispensing revenues are being replaced by launching new services. We must find solutions to reduce the time it takes to dispense medication so we can focus on these new revenue generating services. To not just succeed, but to thrive, it is becoming increasingly important to understand and embrace the technology available.

Covid-19 has accelerated a culture change for community pharmacists. Throughout the pandemic, they have been the first line of advice, treatment and referral for common illnesses, and they have Successfully prevented countless unnecessary visits to A&E. The commitment of the profession to patient care has been widely recognised by both the government and the public. Despite immense pressure, pharmacy teams have risen to the challenges posed by a Global pandemic. "The extent to which pharmacists went over and above the call of duty, acting outside of their licences from a humanity point of view was extraordinary," said Tess Player, vice president and global head of expert and health influencers at GSK Consumer Healthcare, calling them the "unspoken heroes" of Covid-19. Pharmacy teams from around the world have shared with her their experiences. Pharmacists in China remained open round the clock and sourced face coverings for their community and metered out the short supply for their patients.

Researchers from the University of Oxford today (December 8) started recruiting for a clinical trial to test novel antiviral Covid-19 treatments for early use in the illness by people in the community and those who are at higher risk of complications. Partnering with the National Institute for Health Research (NIHR), colleagues in several UK universities, and the NHS UK-wide, the Platform Adaptive trial of NOvel antiviRals for eArly treatMent of Covid-19 In the Community (PANORAMIC), is a national priority trial, and will be open to participants from across the UK. The first treatment to be tested by the UK Antiviral Taskforce will be molnupiravir, a Covid antiviral pill already licensed by the MHRA. Britain became the first country in the world to approve molnupiravir, which was jointly developed by U.S.-based Merck & Co Inc and Ridgeback Biotherapeutics, in November.

In its response to NHS England's consultation on 'the future of vaccination services', the Pharmaceutical Services Negotiating Committee (PSNC) has suggested that a wider range of NHS vaccinations being available from community pharmacies could support the achievement of increased vaccination levels. PSNC said: "Any additional services that contractors could provide can only be considered with additional remuneration above the current global sum in the community pharmacy contractual framework to ensure that the services are adequately resourced." Alastair Buxton, director of NHS Services at PSNC, said: "We've always known, and the evidence supports this, that community pharmacies are one of the most popular and accessible places for people to receive a range of vaccinations. "The NHS was slow to take advantage of this at the start of the Covid-19 pandemic, so we welcome this consultation from them to bring together a wide range of views on the topic. "In the longer-term, if the right funding and support is in place, many pharmacies could help deliver a much wider range of NHS vaccination programmes - giving the public the convenience and service that they want, and taking pressure off our general practice colleagues. It makes perfect sense, and we look forward to the NHS response to this consultation."

Three UK pharmacists are featured in the digital book of celebrations to mark the International Federation of Pharmacists' (FIP) World Pharmacists' Day 2022. Simon Nelson, Nelsons Pharmacy Group, Wales; Raj Rohilla, Midhurst Pharmacy (West Sussex)/Goys Pharmacy (Battersea)/ Hamlins Pharmacy (Shepherds Bush) and Olutayo Arikawe, Swinford Pharmacy, West Midlands were among 27 pharmacists from across the globe and the AmerisourceBergen family, who contributed to a digital book of celebration, which aims to highlight the changing role of pharmacists and how they can create healthier futures. Pharmacists are no longer just 'chemists' - some pharmacists are now able to diagnose, treat and prescribe for patients who traditionally may have needed to see a doctor or GP. Others are guardians of their local community - keeping an eye on vulnerable patients who may not have regular contact with other healthcare professionals. During the Covid-19 pandemic they stepped up to support stretched healthcare systems, with many taking a leading role in the world-wide response. This has evolved further with more and more pharmacists offering vaccination services for Covid-19, as well as flu, chicken pox and 'holiday' vaccinations. This changing role of pharmacists is helping them unite to create healthier futures.

His Royal Highness the Prince of Wales is to host a reception at St James's Palace in early May to celebrate exemplary work of community pharmacist during the Coronavirus pandemic. Up to 200 community pharmacists have been invited by Prince Charles to the event organised to "celebrate community pharmacists", which commences at 5:30pm on Wednesday, May 4 at the London residence of the Prince of Wales. The invitation comes in less than six months after Prince Charles praised community pharmacists for their efforts during the Covid-19 pandemic in a video message sent to the National Pharmacy Association (NPA)'s centenary dinner at Apothecaries' Hall in central London in November last year. He said throughout the pandemic pharmacy teams' "commitment to patient care has never wavered, despite the many enormous pressures you have faced. "During this pandemic period, we have learned, as never before, that pharmacies are one of those vital places where science and society meet. Crucially, they are about people and places, not just pills."

All adults aged 50 years and above are eligible for free flu jabs in England under the autumn Covid-19 booster programme, the Department of Health and Social Care (DHSC) has announced. "The flu virus could also be highly infectious at this time of year, so I am also announcing that those eligible for a free flu vaccination this year will include everyone aged 50 and over, primary school children and secondary school pupils in years 7, 8 and 9, as well as people in clinical risk groups, unpaid carers and household contacts of those who are immunosuppressed," said new health secretary Steve Barclay. Commenting on the DHSC's announcement, CCA chief executive Malcolm Harrison said: "We welcome the decision to accept the advice of the JCVI on who can have free Covid-19 boosters and flu jabs this autumn. Community pharmacies have turbo-charged the Covid-19 vaccination programme over the past 18 months and last year we witnessed the most successful community pharmacy flu campaign ever."

The Pharmacists' Defence Association has reported an increase in the number of pharmacists calling its advice line to inform about the incidences of violence and intimidation from protesters opposing the Covid-19 vaccination programme. The association noted that such incidents have become more common with protesters "gaining entry to premises in groups and trying to disrupt Covid-19 vaccinations from taking place." In many cases, pharmacists, staff, and members of the public have been subjected to verbal threats, causing distress and anxiety among those working to deliver the vaccination programme in a safe environment. The PDA reminded that employers, having a contract with the NHS for the Covid-19 vaccinations, have a duty to keep their staff safe whilst at work. The General Pharmaceutical Council (GPhC) standards for pharmacy premises also carry a duty to ensure the safety of staff and the public receiving services on those premises.

The National Pharmacy Association (NPA) has emphasised that the community pharmacy sector must be involved right from the start in all local planning meetings pertaining to the roll-out of vaccine services in potential future pandemics. This includes crucial discussions regarding supply logistics and resource allocation, lawyers representing the NPA told COVID-19 public inquiry hearing. Chaired by Baroness Heather Hallett, the independent public inquiry is examining the UK's response to the Covid-19 pandemic and lessons for the future. The NPA has been designated as a 'core participant' in Module 4 (vaccines) of the inquiry, which considers various issues related to vaccine development and rollout, as well as Module 3 (healthcare). During the hearing on September 13, NPA lawyers outlined three key areas the association says must be improved in future pandemic vaccination programs, including properly utilising existing primary care expertise, better planning and engagement, and improved access to information for community pharmacists.

The Pharmaceutical Services Negotiating Committee (PSNC) is encouraging community pharmacy contractors to participate in its third Pharmacy Advice Audit due to be held in the week commencing Monday (January 31). The audit is aimed to demonstrate how pharmacies support their communities every day and assist PSNC in gathering evidence for use in the funding discussions with the government and the NHS. It said that last year's Advice Audit provided compelling evidence for use in negotiations with the government and helped in persuading MPs to support the case for Covid-19 costs. PSNC said: "We would therefore be very grateful to anyone able to take part in this year's audit."

Health and social care workers in England, including those working in community pharmacy, will no longer have to have a Covid jab as a condition of employment from later this month, the government said on Tuesday (March 1). The government had announced on January 31 that it intended to revoke the regulations that made vaccination compulsory, subject to the results of a public consultation. The decision was taken because the Omicron strain of the virus was less severe than the Delta variant, and due to high rates of vaccination of people in the UK. Health secretary Sajid Javid told parliament in a written statement that more than 90,000 health and social care workers and members of the public responded to the consultation.

GSK Consumer Healthcare has recently unveiled a three-year programme to support the pharmacy profession with additional practical resources, mental health provisions and proposed policy changes as part of its new report Standing with Pharmacists in the Age of Self-Care. The new report summarises findings from a roundtable hosted by GSK Consumer Healthcare in collaboration with the International Pharmaceutical Federation (FIP) earlier this year, which convened the pharmacy community, policy experts, and industry leaders to discuss the critical role of pharmacy in the age of self-care following the Covid-19 pandemic. "We've seen Covid-19 have a significant impact on consumers' understanding of self-care, leading to an increased focus on wellbeing and everyday healthcare. During this time, pharmacies played a vital role in providing care and advice to their patients - particularly with many other health facilities closed. Our research shows that more than half of Europeans are planning to consult their pharmacist more often than before the pandemic. Yet in general, pharmacists remain under-utilised, despite being the most widely distributed health resource in Europe," said Tess Player, global head of expert at GSK Consumer Healthcare.

There is a realistic possibility of large waves of Covid-19 infection in the future in Britain and such waves might even be considered likely, epidemiologists who model the Covid-19 pandemic to inform government advice have said. Prime minister Boris Johnson has ditched legal restrictions in England, saying that, while the pandemic was not over, Britain needs to learn to live with Covid. The Scientific Pandemic Influenza Group on Modelling, Operational sub-group (SPI-M-O) said the emergence of new viral variants was the biggest unknown factor in the medium-to-long term, along with waning population immunity and changes in mixing patterns. "Large future waves of infection that need active management to prevent detrimental pressure on the health and care sector are, at least, a realistic possibility (high confidence) or likely (medium confidence)," SPI-M-O said in a consensus statement published on Friday.

To support NHS, clear the backlog created by the Covid-19 pandemic and help community pharmacies support more people, the Welsh government has announced an allocation of further £12.5 million funding. Of the total amount, £10mn will be distributed across the 22 local authorities to buy equipment to help people to live independently in their own homes post hospital stay. The remainder, £2.5mn, will be used to support community pharmacists and patients to improve access to treatment and advice for a range of common ailments. The move is aimed at alleviating waiting times and reducing winter pressures on the NHS. Commenting on the announcement, Elen Jones, Royal Pharmaceutical Society director for Wales said: "We are delighted that the Welsh government continue to recognise the value of pharmacists in patient care and we welcome this additional investment and support for Community Pharmacy teams across Wales.

The Department of Health and Social Care (DHSC) has published plans to amend current pharmacy legislation on dispensing errors and clarify how registered pharmacies are governed. The Department's response to a public consultation on rebalancing medicines legislation and pharmacy regulation programme first proposed in summer 2018 was delayed due to Brexit and the Covid-19 pandemic. The programme aims to clarify and strengthen the organisational governance arrangements of registered pharmacies, specifically to define and clarify the core purpose of the Responsible Pharmacist and Superintendent Pharmacist roles. It will also give the General Pharmaceutical Council (GPhC) powers to define in professional standards how those roles are fulfilled.

The Royal Pharmaceutical Society (RPS) has cautioned that measures to protect people against Covid-19 must be stepped up in the wake of discovery of the new variant, B.1.1.529. It has urged members of the public to practice 'hands, face, space and ventilation' protection measures which have become less used in the last few months. RPS director of pharmacy Robbie Turner said that though it was too early to conclude about the transmissibility or resistance of the new variant to current vaccines, quick action should be taken to protect the public. "Each one of us must take the necessary precautions of wearing a mask in higher risk situations, maintaining social distancing wherever possible, ensuring there's appropriate ventilation indoors when meeting others and washing our hands regularly." Encouraging people to take Covid vaccine, he said, it "is still our best defence against this virus".